The Sunday Newsletter - BLEG
Let's recap last week:
The shares are tightly held in strong hands and the trading range and who is in control is absolutely shown that we traders are in control. You can see the resiliency of a strong share structure and what effect it has on the price movement. The weekly chart is absolutely a beautiful sight to see. in the mid .0005We had two days of a downdraft but was short lived and only presented shareholders with opportunities to average in and get lower costs simply to anxiety from shareholders that have lost control of their emotions and trailed the negative sentiment in selling. Only to be amazed how we bounced back that was Wednesday on the misunderstanding on the OTC misclassification which was remedied the next day. I noticed looking at the chart for Friday and noticed another downdraft and this one appears to be somewhat more significant and wanted to confront this with real interest and found by cruising through ihub's posts that somebody wrote that Redditt opened a trading thread. Now this made me feel somewhat relieved since the young Turks over at Redditt do not play well with other children and happen to play outside of their sandbox and throwing sand in everyone's gears. That group over there are notorious for disrupting normal events and believe they caused the dip. As you can see, after the downdraft we went back to normal order and just showed how resilient the trading sessions for the week has been from the previous day's but still within the support of .0055 where we ended Friday with a perfect setup for this week.
The more I look and analysis the company the more I really like it. The main positive is the company currently does not have outstanding promissory, convertible notes, convertible debentures. This is the attractiveness of the company. Reason why I say this is that it is extremely difficult for a Penny Stock to conduct extensive program of Bio-tech research not to have these debt instruments. They have evolved into a very viable company and has put us on a path for solid growth going forward. The R/D is behind us and now we move into a new phase and execute their hard work into an FDA approved business model. The clinical trials.
This phase is the most important and allows the company to maximize their R/D efforts into a legitimate and save environmentally process and very much needed to move forward. It is this stage that will determine the viability of the company's business model. The are a few stages of Clinical trials. This week we have been getting information via twitter that the manufacturing plant is getting their inspection and of course to move forward this has to get the seal of approval before the next step. Let's hope this approval come through without hiccups.
The clinical trials on all companies can take 2-7 years and the latter is usually based on pharmaceutical companies with extensive medical saving medicines like cancer and such. We are not in this category, but nevertheless we do have a product that is eventually going to be used by humans and the procedure in clinical trials is as detailed and exact, but I believe, that a fast-track method and the process won't take as long giving the nature of the product itself.
The corporate structure is in itself a really smart endeavor on the company's part.
Branded Legacy, Inc. is a holding company that specializes in alkaloid extraction, refinement, and synthesis, as well as formulation and co-packing. Its primary focus is the commercial development of alkaloid-infused products such as vapes, tinctures, topicals, and gummies. We have a secondary focus on brand development, marketing, and overall sustainability. This on the surface details what the company is all about, but the underpinning or its corporate makeup is what is very important and just plain smart in the building the entire thesis.
See the company is built on the Vertical Organizational Structure: This departmental structure is an absolute way of allowing all steps of the company to be run by inhouse top tier management and its departments to the raw materials to the end product and finally into the sales end and onto the public domain. No disruptions from outsourcing or any delays that encompass many companies that rely beyond their control. Not here. The company is fully integrated. Good for the company and great for us shareholders ROI.
The acquisition of the various partnership/collaborations is what makes this a superb company. They kept on board the same teams of top management that was in the acquisition allowing for a unified transfer without embarking on a new team to familiarize with the organizational aspect that narrowed the time constraints for up and running into the new entity. Smart indeed.
List any subsidiaries, parent company, or affiliated companies:
Total Refinement Solutions, LLC (DBA Royal Biotek) is a wholly owned subsidiary with a proven track record of quality and efficiency. Our operations focus on the extraction, refinement, synthesis, and formulation necessary to support our co-packing endeavors. We have patentable intellectual property including product formulations and standard operating procedures. We perform extraction/refinement services both for our in house brands as well as on contract for our external partners. Our assets include a state of the art lab facility capable of processing several hundred kilograms of raw material per day.
The Alcannabist, LLC is a wholly owned subsidiary specializing in proprietary formulations encompassing a range of wellness products containing CBD, Mitragynine, Kavatones, and functional mushrooms. Its mission is to provide effective, natural solutions for various health concerns while also serving as an open market hub for marketing and distributing related products. With several product lines specifically formulated to treat migraine headaches, anxiety, pain, sleeplessness, and others, we offer vapes, gummies, tinctures, and topicals.
Rocket Web Development and Design, LLC (RWDD) is another wholly owned subsidiary, and is a leading web development company that has been developing and supporting various businesses in multiple industries for the past 7 years. Our consistent growth over this period has been a testament to our commitment to quality, innovation, and client satisfaction.
RWDD is revolutionizing our digital capabilities with its bespoke web development and comprehensive digital marketing solutions. This strategic integration not only enhances our subsidiaries' online presence but also extends these advanced services to our clients, promising a significant boost in digital engagement and market reach.
MaryJ Pharmaceuticals, Inc. is a wholly owned subsidiary whose primary service is a full-service mobile provider in the Medicinal Marijuana & HEMP industry. This would include everything from portable extraction, packaging, HIPPA compliant RFID tracking from seed to sale, delivery services, white labeling, retail products and research & development
You can see the importance of the Vertical Organizational Structure. Totally in the right direction a perfect setup for the growth of the company.
What can we now expect with respect to Shareholders ROI in the coming weeks and months?
We will be getting news on updates with the manufacturing process and let's hope we get a good bill of health. A passing grade to move us forward. I see that if all is well, we will move into copper no later than the end of May. In other words, I expect us to see copper in the next 2 weeks without much difficulty. This is also with the upcoming quarterly expect on May 15 for the first quarter of 2024. This will give us direct and hopefully good numbers. The numbers on the recent acquisition of MaryJ won't be in this quarter, but certainly in the 3rd after the growing season. The company was halting operation because of Covid.
Folks this is in a nutshell the overlook of what is coming and expected in the next few months going into the end of the year. As I have mentioned, the share price of .01 will happen shortly and once we move into clinical trials and the positive outcome to allow us moving forward .02.05 beyond the first half of 2025 is very doable. Our trading ranges from now to end of year will be .01-.025. It is after the clinical trials where the rubber meets the road.
See you all on the trading floor tomorrow.
Have a good day.
varok
